文献速递淋巴瘤

初治免疫化疗滤泡性淋巴瘤的简化评分系统

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
PubMed 文献 · Blood · 2018-04-17

在PRIMA试验1135例初治R-化疗±R维持的滤泡性淋巴瘤患者中验证FLIPI和FLIPI2,并开发仅含骨髓受累和β2微球蛋白的PRIMA-PI评分,分高、中、低危三组,5年PFS率分别为37%、55%、69%(P < .0001),外部验证队列479例结果一致。

要点

  • PRIMA-PI仅含骨髓受累和β2微球蛋白两个参数,分高、中、低危三组。
  • PRIMA-PI低、中、高危组5年PFS率分别为69%、55%、37%(P < .0001)。
  • 外部验证队列479例5年EFS率低、中、高危组分别为77%、57%、44%(P < .0001)。

核心结论

  • PRIMA-PI是适用于初治免疫化疗患者的新颖且易于计算的预后指数,可作为构建更复杂整合生物分子评分的基础。

研究设计与样本

  • 在PRIMA试验1135例初治接受R-化疗±R维持治疗的患者队列中验证FLIPI和FLIPI2,并开发新预后工具。
  • 外部验证采用FL2000 LYSA试验和University of Iowa/Mayo Clinic淋巴瘤SPORE分子流行病学资源库的479例患者汇总队列。

主要发现

  • PRIMA-PI高危为β2m > 3 mg/L,低危为β2m ≤ 3 mg/L且无骨髓受累,中危为β2m ≤ 3 mg/L伴骨髓受累。
  • PRIMA-PI低、中、高危组5年PFS率分别为69%、55%、37%(P < .0001)。
  • 24个月时达到或未达到EFS(EFS24)是后续总生存的强治疗后预后参数,且PRIMA-PI与EFS24相关。
  • 外部验证队列PRIMA-PI低、中、高危组5年EFS率分别为77%、57%、44%(P < .0001)。

关键数值与推荐

  • PRIMA-PI风险分组:高危β2m > 3 mg/L;低危β2m ≤ 3 mg/L且无骨髓受累;中危β2m ≤ 3 mg/L伴骨髓受累。

临床怎么用

  • PRIMA-PI可用于初治免疫化疗滤泡性淋巴瘤患者的预后分层,作为试验分层和构建生物分子评分的基础。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of patients treated with initial immunochemotherapy. There is currently a need to define parsimonious clinical models for trial stratification and to add on biomolecular factors. Here, we confirmed the validity of both the follicular lymphoma international prognostic index (FLIPI) and the FLIPI2 in the large prospective PRIMA trial cohort of 1135 patients treated with initial R-chemotherapy ± R maintenance. Furthermore, we developed a new prognostic tool comprising only 2 simple parameters (bone marrow involvement and β2-microglobulin [β2m]) to predict progression-free survival (PFS). The final simplified score, called the PRIMA-PI (PRIMA-prognostic index), comprised 3 risk categories: high (β2m > 3 mg/L), low (β2m ≤ 3 mg/L without bone marrow involvement), and intermediate (β2m ≤ 3 mg/L with bone marrow involvement). Five-year PFS rates were 69%, 55%, and 37% in the low-, intermediate-, and high-risk groups, respectively (P < .0001). In addition, achieving event-free survival (EFS) or not at 24 months (EFS24) was a strong posttreatment prognostic parameter for subsequent overall survival, and the PRIMA-PI was correlated with EFS24. The results were confirmed in a pooled external validation cohort of 479 patients from the FL2000 LYSA trial and the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. Five-year EFS in the validation cohort was 77%, 57%, and 44% in the PRIMA-PI low-, intermediate-, and high-risk groups, respectively (P < .0001). The PRIMA-PI is a novel and easy-to-compute prognostic index for patients initially treated with immunochemotherapy. This could serve as a basis for building more sophisticated and integrated biomolecular scores.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018. PMID: 29666118. doi:10.1182/blood-2017-11-816405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。